Vanda Pharmaceuticals (VNDA) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Vanda Pharmaceuticals (VNDA) over the past year, gaining 45.9% versus a loss of 16.1%. Over five years, VNDA leads with a -75.2% price change compared with -96.5% for ZNTL. Vanda Pharmaceuticals is the larger company by market cap ($276.3 million vs $259.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VNDA | ZNTL |
|---|---|---|
| Share price | $4.57 | $2.64 |
| Market cap | $276.31M | $259.04M |
| 1-day change | +0.88% | +5.18% |
| YTD return | -48.19% | +95.56% |
| 1-year return | -16.15% | +45.86% |
| 5-year return | -75.18% | -96.48% |
| Forward P/E | 22.85 | — |
| EPS (TTM) | $-4.63 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.94 | $6.95 |
| 52-week low | $4.27 | $1.21 |
| Distance from 52-week high | -54.02% | -62.01% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +157.11% | +177.65% |
| Average volume | 975.01K | 1.20M |
| Shares outstanding | 60.46M | 98.12M |
| Employees | 533 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed VNDA by 62.0 percentage points over the past year.
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
VNDA vs ZNTL FAQ
Which is bigger, Vanda Pharmaceuticals or Zentalis Pharmaceuticals?
Vanda Pharmaceuticals (VNDA) is larger, with a market capitalization of $276.31M compared with $259.04M for Zentalis Pharmaceuticals (ZNTL).
Which stock has performed better over the past year, VNDA or ZNTL?
ZNTL returned +45.86% over the past 12 months, compared with -16.15% for VNDA (price return, excluding dividends). Past performance does not predict future results.
Are Vanda Pharmaceuticals and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.